CINITAPRIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H30N4O4
Molecular Weight	402.4873
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CCOC1=C(C=C(C(N)=C1)[N+]([O-])=O)C(=O)NC2CCN(CC3CCC=CC3)CC2

InChI

InChIKey=ZDLBNXXKDMLZMF-UHFFFAOYSA-N

InChI=1S/C21H30N4O4/c1-2-29-20-13-18(22)19(25(27)28)12-17(20)21(26)23-16-8-10-24(11-9-16)14-15-6-4-3-5-7-15/h3-4,12-13,15-16H,2,5-11,14,22H2,1H3,(H,23,26)

HIDE SMILES / InChI

Molecular Formula	C21H30N4O4
Molecular Weight	402.4873
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

Cinitapride is an agonist of 5-HT4 and 5-HT1 receptors and antagonist of 5-HT2 receptors. Cinitapride is marketed worldwide for the treatment of gastrointestinal disorders related to motility such as indigestion or functional or non-ulcer dyspepsia, gastroesophageal reflux diseases, delay in gastric emptying and vomiting.